Does Allergy Immunotherapy Work? SCIT, SLIT, and OIT Compared by Allergen

SCIT (subcutaneous immunotherapy) delivers allergen extracts via injection under the skin at a clinic. SLIT (sublingual immunotherapy) delivers allergens as tablets or drops held under the tongue, and can be taken at home after the first supervised dose. OIT (oral immunotherapy) delivers food allergens in gradually increasing doses by mouth and is currently approved only for peanut allergy (Palforzia) in the US. The key distinctions: SCIT has the broadest allergen coverage and longest evidence base; SLIT has superior safety and convenience for its approved allergens; OIT is the only modality appropriate for food allergies. Each modality requires at least 3 years of consistent treatment to achieve durable, disease-modifying benefit.

SCIT does not treat food allergies and attempting it would be dangerous — subcutaneous delivery of food allergens carries an unacceptably high risk of systemic anaphylaxis. The appropriate modality for food allergy is OIT. Palforzia, an FDA-approved peanut OIT product, allowed 67.2% of peanut-allergic patients to tolerate 600 milligrams of peanut protein (approximately two peanuts) after 12 months of treatment, compared to only 4% of placebo patients in the PALISADE trial. Investigational OIT protocols for milk, egg, and tree nuts are in clinical trials. One nuance: some patients with pollen-food allergy syndrome (oral allergy syndrome) see improvement in mild food-related symptoms after pollen SCIT — but this indirect benefit does not constitute food allergy treatment and does not protect against anaphylaxis.

Most patients notice symptom improvement within the first allergy season, typically 3 to 6 months into treatment for both SCIT and SLIT. However, the full disease-modifying benefit — including sustained relief that lasts after stopping treatment — requires at least 3 years of consistent immunotherapy. Research by Scadding et al. in the GRASS trial (2017) showed that 2-year SCIT and SLIT courses both failed to produce durable post-treatment benefit, confirming that 3 years is the minimum threshold. The Calderon Cochrane review notes that patients begin experiencing meaningful symptom reduction during the first year of treatment, with effects growing year over year as immunological tolerance builds.

Immunotherapy is not a cure in the traditional sense, but it produces disease modification that can last years after stopping treatment. The landmark Durham et al. 1999 New England Journal of Medicine study showed grass pollen SCIT produced symptom and medication scores that remained significantly lower than untreated controls for at least 3 years after stopping a 3 to 4 year course. Pediatric data from Eng et al. followed patients 12 years after stopping SCIT and found persistent clinical benefit and reduced new sensitizations. A minority of patients experience gradual relapse, particularly those with ongoing high allergen exposure, and may need a second course. The key distinction from medications is that immunotherapy's effects persist after stopping; antihistamines and corticosteroids provide no lasting benefit once discontinued.

SCIT has proven efficacy for a wide range of aeroallergens. The strongest evidence supports grass pollen, house dust mites, ragweed, cat dander, and Alternaria mold. Moderate evidence exists for birch and tree pollens. Evidence for dog, cockroach, and other molds is weaker or negative in recent trials. SCIT does NOT treat food allergies safely and is not used for that purpose. Venom immunotherapy (VIT), a specialized SCIT protocol, provides 95-98% protection against future systemic reactions from bee, wasp, and other stinging insect stings — the highest efficacy rate of any immunotherapy category. Your allergist will test which specific allergens drive your symptoms before designing a treatment mix.

Success rates vary by modality and allergen type. For SCIT, roughly 50 to 80% of treated patients achieve clinically meaningful improvement in observational cohorts, with some studies showing 76.6% cumulative clinical remission for dust mite SCIT at 5 years. The Calderon Cochrane review found a pooled SMD of -0.73 for symptom reduction — roughly a one-third reduction in severity — across 51 randomized trials. For FDA-approved SLIT tablets, symptom reductions of 20 to 35% versus placebo are consistently reported. Real-world success rates are lower than trial data suggest because only 18 to 45% of patients complete the recommended 3-year course — adherence is the dominant practical limitation on immunotherapy effectiveness.

Adults of any age can start allergy immunotherapy, and the evidence shows comparable efficacy between adults and children. Meta-analyses from the Calderon Cochrane review show no statistically significant difference in symptom or medication score reduction between adult and pediatric populations receiving SCIT. Adults over 65 should have a benefit-risk assessment given potential comorbidities, but AAAAI practice parameters specify no upper age limit for SCIT initiation. The one important age-related difference is disease modification: children who start SCIT gain stronger prevention of new sensitizations and asthma onset, while adults achieve excellent symptom control and medication reduction but miss this early-intervention disease-prevention window. For adults who have suffered for decades, starting SCIT at 40 or 50 still provides 3 to 12 years of post-treatment benefit — a substantial quality-of-life gain.